Antisense oligonucleotides in psychopharmacology and behaviour: Promises and pitfalls

Journal of Psychopharmacology

Volumn 11, Issue 3, 1997, Pages 259-269

  Robinson, E S J ^a   Nutt, D J ^a   Jackson, H C ^b   Hudson, A L ^a  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Antisense oligonucleotides; Behavioural pharmacology; Brain receptors; Gene inhibition; Messenger RNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BRAIN PROTEIN; BRAIN RECEPTOR; EXCITATORY AMINO ACID; MESSENGER RNA; MONOAMINE; NEUROPEPTIDE; OPIATE; OPIATE RECEPTOR; PROTEIN C FOS;

ANIMAL CELL; ARTICLE; BEHAVIOR; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMEDIATE EARLY GENE; METHODOLOGY; MOLECULAR GENETICS; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOPHARMACOLOGY; TRANSCRIPTION REGULATION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PSYCHOPHARMACOLOGY; RECEPTORS, NEUROTRANSMITTER;

EID: 0030846807     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100310     Document Type: Article

References (103)

1. Agrawal S, Goodchild J, Civeira MP, Thornton AT, Sarin PM, Zamecnik P C (1988) Oligodeoxynucleoside phosphoramidites and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Nat Acad Sci USA 85: 7079-7083
2. Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Nat Acad Sci USA 88: 7595-7599
3. Akabayashi A, Wahlestedt C, Alexander JT, Leibowitz SF (1994) Specific inhibition of endogenous neuropeptide Ysynthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behaviour and insulin secretion. Mol Brain Res 21: 55-61
4. Anazodo M I, Wainberg M A, Friesen A D, Wright J A (1995) Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate. Leukaemia 9 (Suppl. 1): S86-S88
5. Bennett C F, CondonT P, Grimm S, Chan H, Chain M-Y (1994) Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 152: 3530-3540
6. 6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmac Exp Ther 274: 173-180
7. Brysch W, Schlingensiepen K-H (1994) Design and application of antisense oligonucleotides in cell culture, in vivo and as therapeutic agents. Cell Mol Neurobiol 14: 555-567
8. Campbell JM, Bacon TA, Wickstrom E (1990) Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Meth 20: 259-267
9. 1 receptor subunit. Br J Pharmac 114: 324P
10. Chen X-H, Adams J U, Geller E B, DeRiel J K, Adler M A, Liu-Chen L-Y (1995) An antisense oligodeoxynucleotide to μ-opioid receptors inhibit μ-opioid receptor agonist-induced analgesia in rats. Eur J Pharmac 275: 105-108
11. Chiasson B J, Hooper M L, Murphy P R, Robertson H A (1992) Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur J Pharmac - Mol Pharmac Sec 227: 451-453
12. Chiasson B J, Armstrong J N, Hooper M L, Murphy P R, Robertson H A (1994) The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell Mol Neurobiol 14:507-521
13. Chiang M Y, Chan H, Zounes M A, Freier S M, Lima W F, Bennett C F (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266: 162-171
14. Chien C C, Brown G, Pan X-Y, Pasternak G W (1994) Blockade of U50, 488H analgesia by antisense oligodeoxynucleotides to a κ-opioid receptor. Eur J Pharmac 253: R7-8
15. Cooke S T (1992) Therapeutic applications of oligonucleotides. Ann Rev Pharmac Toxicol 32: 329-376
16. Davis M (1992) The role of the amygdala in fear and anxiety. Ann Rev Neurosci 15: 353-375
17. Di Scala-Guenot D, Strosser MT, Freund-Mercier M J, Richard P (1990) Characterisation of oxytocin-binding sites in primary rat brain cell cultures. Brain Res 524: 10-16
18. Dragunow M, Lawlor P, Chaisson B, Robertson H (1993) C-fos antisense generates apomorphine and amphetamine-induced rotation. Neuroreport 5: 305-306
19. Dunn A J, Berridge C W (1990) Physiological and behavioural response to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress response? Brain Res Rev 15: 71-100
20. Eckstein F (1983) Phosphorothioate analogues of nucleotides -tools for the investigation of biochemical processes. Ang Chem 22: 423-506
21. Evans C J, Keith D E Jr, Morrison H, Magendzo K, Edwards R H (1992) Cloning of a delta opioid receptor by functional expression. Science 258: 1952-1955
22. Fukuda K, Katto S, Mori K, Nishi M, Takeshima H (1993) Primary structures and expression from cDNAs of rat opioid receptors from δ and μ -subtypes. FEBS Letts 327: 311-314
23. Graybiel A M, Moratalla R, Robertson H A (1990) Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Nat Acad Sci USA 87: 6912-6916
24. Guinosso C J, Hoke G J, Ecker D J, Mirabelli C K, Crooke S T, Cook P D (1991) Synthesis, biophysical and biological evaluation of 2′-modified antisense oligonucleotides. Nucleosides Nucleotides 10: 259-265
25. Heilig M, Engel J A, Söderpalm B (1993) C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine. Eur J Pharmac 236: 339-340
26. Heilig M (1994) Antisense technology. Prospects for treatment of neuropsychiatrie disorders. CNS Drugs 1: 405-409
27. Helene C (1994) Control of oncogene expression by antisense nucleic acids. Eur J Cancer 11: 1721-1726
28. Holsboer F, Spengler D, Heuser I (1992) The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorder and dementia. Prog Brain Res 93: 385-417
29. Hooper M L, Chaisson B J, Robertson H A (1994) Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioural effect. Neuroscience 63: 917-924
30. Hoyer D, Clarke D E, Fozard J R, Hartig P R, Martin G R, Mylecharane E J, Saxena P R, Humphrey P P A (1994) VII International Union of Pharmacology classification of receptor for 5-hydroxytryptamine (serotonin). Pharmac Rev 46: 157-203
31. Johnson R S, Spiegelman B M, Papaioannou V (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71: 577-586
32. Juliano R L, Akhtar S (1992) Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res Dev 2:165-176
33. A gamma 2 subunit induces loss of neurones in rat hippocampus. Neurosci Letts 202:97-100
34. Kean J M, Kipp S A, Miller P S, Kulka M, Aurelian L (1995) Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry 34: 14617-14620
35. Kieffer B L, Befort K, Gaveriaux-Ruff C, Hirth C G (1992) The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterisation. Proc Nat Acad Sci USA 89: 12048-12052
36. Kirkland M A, O'Brian S G, McDonald C, Davidson R J, Cross N C R, Goldman J M (1993) BCR-ABL antisense purging in chronic myeloid leukaemia (3). Lancet 342: 614
37. Kitajama I, Shinohara T, Bilakovics J, Brown D A, Xu X, Nerenberg M (1993) Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-Kappa B. Science 258: 1792-1795
38. Koob G F (1992) Dopamine addiction and reward. Semin Neurosci 4: 139-148
39. Korba B E, Gerin J L (1995) Antisense oligonucleotides are effective inhibitors of hepatitis B replication in vitro. Antiviral Res 28: 225-242
40. Koschel K, Brinckmann U, Hoyningen-Huene V V (1995) Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology 207: 168-178
41. Krieg A M (1993) Uptake and efficacy of phosphodiester and modified antisense oligonucleotides in primary cell cultures. Clin Chem 39: 710-712
42. Krieg A M, Tonkinson J, Matson S, Zhao Q, Saxon M, Zhang L-M, Bhanja U, Yakubov L, Stein C A (1993) Modification of a phosphodiester oligodeoxyribonucleotide by a 5′-cholesteryl moiety increases cellular association and improves efficacy. Proc Nat Acad Sci USA 90:1048-1052
43. Lai J, Bilsky E J, Porreca F (1995) Treatment with antisense oligodeoxynucleotide to a conserved sequence of opioid receptors inhibits antinociceptive effects of delta subtype selective ligands. J Recept Sig Transd Res 15: 643-650
44. 1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behaviour in rats. J Neurosci 15: 4250-4258
45. LeDoux J E (1992) Brain mechanisms of emotion and emotional learning. Curr Opin Neurobiol 2: 191-197
46. McCarthy M M, Brooks B J, Pfaus J, Brown H E, Flanagan L M, Schwartz-Giblin S, Pfaff D N (1993) Antisense technology in behavioural neuroscience. Neuroprotocols 2:67-74
47. Mani S K, Blaustein J D, Allen J M C, Law S W, O'Malley B W, Clark J H (1994a) Inhibition of rat sexual behaviour by antisense oligonucleotides in the progesterone receptor. Endocrinology 135: 1409-1414
48. Mani S K, Allen J M C, Clark J H, Blaustein J D, O'Malley B W (1994b) Convergent pathways for steroid hormone and neurotransmitter-induced rat sexual behaviour. Science 265: 1246-1249
49. Meeker R, LeGrand G, Ramirez J, Smith T, Shih Y-H (1995) Antisense vasopressin oligonucleotides: Uptake, turnover, distribution, toxicity and behavioural effects. J Neuroendocrinol 7: 419-428
50. Meldrum B S (1992) Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res 12: 189-196
51. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmac Sci 11: 379-387
52. Meng F, Xie G-X, Thompson R C, Mansour A, Goldstein A, Watson S J, Akil H (1993) Cloning and pharmacological characterisation of a rat kappa-opioid receptor. Proc Nat Acad Sci USA 90: 9954-9958
53. Miller P S, McFarland K B, Jayaraman K, Ts'o POP (1981) Biochemical and biological effects of non-ionic nucleic acid methylphosphonates. Biochemistry 20: 1874-1880
54. Möller C, Bing O, Heilig M (1994) C-fos expression in the amygdala: in vivo antisense modulation and role in anxiety. Cell Mol Neurobiol 14: 415-423
55. Narita M, Tseng L F (1995) Stimulation of spinal δ-opioid receptors in mice selectively enhances the attenuation of δ-opioid receptor-mediated antinociception by antisense oligodeoxynucleotide. Eur J Pharmac 284: 185-189
56. 3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport 6: 573-576
57. 2-adrenoceptors and blood pressure regulation in the rat. Eur J Pharmac 278: 183-185
58. Ogawa S, Brown H E, Okano H J, Pfaff D N (1995) Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Reg Pep 59:143-149
59. Owens M J, Bissette G, Nemeroff C B (1989) Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse 4: 196-202
60. Owens M J, Nemeroff C B (1991) The physiology and pharmacology of corticotropin-releasing factor. Pharmac Rev 43: 425-473
61. 3-related opioid receptor. Mol Pharmac 47: 1180-1188
62. Pasternak G W, Standifer K M (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology.Trends Pharmac Sci 16: 344-350
63. Richardson N R, Piercy M F, Svensson K, Collins R J, Myers J E, Roberts D C (1993) Antagonism of cocaine self-administration by preferential dopamine autoreceptor antagonist, (+)-AJ 76. Brain Res 619: 15-23
64. Roth B L, Craigo S C, Choudhary M S, Uluer A, Monsma F J, Shen Y, Meltzer H Y, Sibley D R (1994) Binding of typical and atypical antipsychotic agents of 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmac Exp Ther 268: 1403-1410
65. 6) receptor: molecular cloning, localisation and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193: 269-276
66. Seeman P, Lee T, Chau-Wang M, Wang K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
67. Seeman P (1980) Brain DA receptors. Pharmac Rev 32: 229-313
68. 2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Mol Pharmac 46: 51-57
69. Simons M, Edelman E R, DeKeyser J-L, Langer R, Rosenberg R D (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359: 67-70
70. Skutella T, Montkowski A, Stöhr T, Probst J C, Landgraf R, Holsboer F, Jirikowski G F (1994a) Corticotrophin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell Mol Neurobiol 14: 579-588
71. Skutella T, Probst J C, Jirikowski G F, Holsboer F, Spangel R (1994b) Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behaviour in rats. Neurosci Letts 167: 55-58
72. 7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. J Pharmac Exp Ther 47: 99-103
73. Smith D W, Parker E M (1995) G protein-coupled serotonin receptors - multiple subtypes, multiple opportunities. Curr Pharmaceut Des: 1:363-372
74. 3) as a target for neuroleptics. Nature 347: 146-151
75. Sommer W, Bjelke B, Ganten D, Fuxe K (1993) Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to d-amphetamine. Neuroreport 5: 277-280
76. Standifer K M, Chien C-C, Wahlestedt C, Brown G P, Pasternak G W (1994) Selective loss of δ opioid analgesia and binding by a δ opioid receptor. Neuron 12: 805-810
77. Stein C A (1992) Antisense oligonucleotides - promises and pitfalls. Leukemia 6: 967-974
78. Stein C A, Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261: 1004-1012
79. Stephenson M L, Zamecnik P C (1978) Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Nat Acad Sci USA 75: 285-288
80. Strauss M, Hering S, Lieber A, Herrmann G, Griffin B E, Arnold W (1992) Stimulation of cell division and fibroblast focus formation by antisense repression of retinaoblastoma protein synthesis. Oncogene 7: 769-773
81. Sun F-S, Faden A I (1995) Pretreatment with antisense oligodeoxy-nucleotides directed against the NMDA-R1 receptor enhances survival and behavioural recovery following traumatic brain injury in rats. Brain Res 693: 163-168
82. Takizawa S, Hogan M, Hakim AM (1991) The effect of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pH in focal ischaemia. J Cereb Blood Flow Metab 11: 786-793
83. Thomas E (1988) Forebrain mechanisms in the relief of fear: The role of the lateral septum. Psychobiology 16: 36-44
84. Toulme JJ (1992) Artificial regulation of gene expression by complementary oligonucleotides - an overview. In Antisense RNA and DNA. Wiley-Liss, New York, pp. 175-194
85. Vogel J R, Beer R, Clodt D E (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21: 1-7
86. 1 dopamine receptor agonist SKF38393 in the rat. Psychopharmacology 109: 41-48
87. Wagner R W, Matteucci M D, Lewis J G, Gutierrez A Z, Moulds S C, Fruehler B C (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimadines. Science 260: 1510-1513
88. Wagner R W (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333-335
89. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Inturrisi C E, Reis D J (1993a) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurones from excitotoxicity and reduce focal ischaemic infarctions. Nature 363: 260-263
90. Wahlestedt C, Merlo-Pich E, Koob G F, Yee F, Heilig M (1993b) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259: 528-531
91. Wahlestedt C (1994) Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmac Sci 15: 42-46
92. Walder R Y, Walder J A (1988) Role of RNaseH in hybrid-arrested translation by antisense oligonucleotides. Proc Nat Acad Sci 85: 5011-5015
93. Wang Z Q, Ovitt C, Grigoriadis A E, Mohle-Steinlein U, Ruther U, Wagner E F (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741-745
94. 2 mRNA. Neuroscience 55: 607-612
95. Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger J R, Neckers L M (1993) Stability, clearance and deposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Nat Acad Sci USA 90: 4665-4669
96. Wickstrom E (1986) Oligonucleotide stability in subcellular extracts and culture media. J Biochem Biophys Meth 13: 97-102
97. Woolf T M, Melton D A, Jennings C G B (1992) Specificity of antisense oligonucleotides in vivo. Proc Nat Acad Sci USA 89: 7305-7309
98. 2 receptors: behaviour correlates. Neurosci Letts 161: 223-226
99. 1 dopamine receptor-mediated behaviours in normal mice and in mice lesioned with 6-hydroxydopamine. J Pharmac Exp Ther 271: 1462-1470
100. 2 receptor subtypes in locomotor activity and stereotypy: Antisense knockout studies. Soc Neurosci Abstr 21: 364
101. 2 dopamine receptor mRNA. Neurochem Int 22:301-311
102. 2 dopamine agonists but contralateral rotations to muscarinic cholinergic agonists. J Pharmac Exp Ther 264: 824-830
103. 2 dopamine receptors in mouse striatum. J Pharmac Exp Ther 268:1015-1023